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In the present study (Aapro et al, 2009), results of an updated
meta-analysis of 12 randomised controlled trials with 2297 patients
are presented on the effects of Epoetin b on survival, tumour
progression and thromboembolic events (TEEs) in cancer patients.
Special emphasis is given to the impact of different haemoglobin
(Hb) levels at initiation of Epoetin b treatment. Overall, the risk for
death was increased by a factor of 1.13 (95% CI 0.87–1.46) and
that for thromboembolic events was increased by a factor of 1.62
(95% CI 1.13–2.31) in patients receiving Epoetin b compared with
controls. When the analysis was limited to patients receiving
Epoetin b at Hbp10gdl
 1, the authors identified no evidence for a
negative impact on survival (Epoetin b vs control HR 0.99, 95% CI
0.70–1.40) and a favourable effect for disease progression (HR
0.73, 95% CI 0.57–0.94). However, the authors describe an
increased risk for death in patients with Hb levels of 411gdl
 1
at initiation of Epoetin b therapy.
To evaluate the effect of baseline haemoglobin level on overall
survival and other outcomes, Aapro et al. stratified the data by
entry Hb and compared the treatment estimates in such created
subgroups. Based on this analysis, the authors conclude that no
detrimental effect of Epoetin b on survival or tumour pro-
gression is apparent when initiated at Hb levels up to 11gdl
 1.
However, no statistical test for heterogeneity between subgroups
was conducted. Accordingly, it is debatable whether the observed
differences in treatment effects between entry Hb subgroups is
due to entry Hb acting as an effect modifier or is just a play of
chance. For two subgroups, a Z test on heterogeneity (Borenstein
et al, 2009) can be calculated from estimated treatment effects and
width of confidence intervals in the respective subgroups. The
Z test on heterogeneity is based on the difference in the two
estimated treatment effects divided by a pooled standard error.
Information to conduct this test is given in Figure 2 of Aapro et al.
for overall survival and other outcomes. For overall survival, a
Z test for heterogeneity comparing the subgroups entry
Hbp11gdl
 1 and entry Hb411gdl
 1 would yield a P-value of
0.65. This test would also be non-significant for progression-free
survival (P¼0.36) and time to TEE (P¼0.90). Bohlius et al (2009)
also evaluated baseline Hb level as a potential effect modifier of
treatment with erythropoiesis-stimulating agents in a larger
dataset with 13407 cancer patients using a Cox regression model
stratified by study. The analysis with five Hb subgroups yielded a
P-value of 0.75.
The authors consider target haemoglobin level as a potential
effect modifier. Target Hb level was defined as the maximum Hb
level actually achieved up to 28 days after the end of treatment,
which is time-dependent information. Using the maximum Hb
level during follow-up for stratification is problematic for several
reasons. Patients are divided into subgroups based on future
information, which requires a specialised methodology in survival
data with censored observations. Furthermore, the maximum Hb
level during follow-up is dependent on the Epoetin b dosage, as
well as other factors such as disease severity and number of blood
transfusions. Accordingly, as correctly pointed out by the authors
in the discussion, results of the analysis of target Hb level need to
be interpreted with caution because of methodological limitations
and potential confounding (see also Altman and de Stavola, 1994).
In addition, interpretation of the results for maximum Hb level
achieved is difficult, as it is unclear which effect is actually
estimated in subgroups that are created by stratifying on
information that is not available before the follow-up ends, either
because the patient may die or is lost to follow-up. A more
interpretable analysis of target Hb levels could be based on a Cox
regression model containing both baseline Hb level and time-
dependent Hb level as covariates (Parmar and Machin, 1995).
Furthermore, in such Cox regression models, time-dependent
information is modelled appropriately and the effect of future Hb
values in addition to the baseline Hb level can be quantified and
tested against the null hypothesis that future Hb values do not
contain any additional information.
Evaluating the impact of haemoglobin levels on survival and
other outcomes in cancer patients treated with Epoetin b is an
important research topic. The authors give some indications on
the safety of Epoetin b when used within the Hb intervention and
target levels as recommended in the revised European label.
However, in order to get a more definite answer on the impact of
initial and target haemoglobin levels on survival outcomes,
analysis in a larger dataset using appropriate statistical methods
for time-dependent information would be essential. *Correspondence: Dr G Schwarzer; E-mail: sc@imbi.uni-freiburg.de
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